Identity
Roche Diagnostics, S.L.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €68.2M | |
| 2025 | €96.5M | |
| 2024 | €39.9M | |
| + regional platforms | ||
| 2023 | €36.3M | |
| 2022 | €28.9M | |
| 2021 | €65.2M | |
| 2020 | €38.8M | |
| 2019 | €13.8M | |
| 2018 | €9.6M | |
| 2017 | €4.0M | |
| 2016 | €0.9M | |
In figures
Volume
Between 2016 and 2026 it won 868 contracts worth €402M on its own, with 119 buyers. Its 2 joint-venture (UTE) contracts are shown separately.
Price
In 2024–2026 its median discount was 15.3%; the middle half of its discounts between 7.4% and 28.4% (28 comparable awards).
Competition
Since 2024, 25% of its comparable value was won with a discount and against other bidders. It was the only bidder in 83% of its contracts (2016–2026).
Renewals
109 contracts (€82.7M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Roche Diagnostics, S.L.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Roche Diagnostics, S.L.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 15.3% · middle half between 7.4% and 28.4% · 28 awards
2017–2023: median 15.8% (59 awards) · 2024–2026: median 15.3% (28 awards).
2017–2026: median 15.5% · middle half between 5.9% and 24.5% · 87 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
By sector
Productos farmacéuticos
CPV 336
171 contracts · €185M
Equipamiento médico
CPV 331
39 contracts · €10.5M
By buyer · 2024–2026
Departamento de Salud de Castellón. Dirección Económica-Gerencia
Productos farmacéuticos
14 contracts · €54.5M
Dirección General de Planificación Económica
Productos farmacéuticos
3 contracts · €31.8M
Centro de Gestion Integrada y Proyectos Corporativos
Productos farmacéuticos
17 contracts · €12.4M
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
20 awards at the tender price, left out of the discounts.
How it wins
Whether it wins with or without competition.
63% of the comparable value since 2024 (€80.9M of €128M) was won with a discount and without other bidders. €32.6M (25%) was awarded with a discount and against other bidders.
Comparable: 101 awards with a published budget and bidder count (€128M of €205M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 82.1% of the value was awarded through open procedure (35.9% of contracts); followed by Negotiated without publicity (14.4%) and Based on a framework agreement (1.8%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 109 of its contracts come up for tender again, worth €82.7M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Hospital Universitario de Móstoles | €112k |
| 2026 | Jefatura de la Sección Económico Administrativa 15 Agrupación del Cuartel General del Ejército del Aire | €75.4k |
| 2026 | Organismo Autónomo Madrid Salud | €60.9k |
| 2026 | Hospital Universitario de Móstoles | €23.0k |
| 2026 | Hospital Universitario de Móstoles | €20.7k |
and 104 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Departamento de Salud de La Plana. Dirección Económica-Gerencia | 45 | 85 M | 2017–2026 |
| Secretaria General del Servicio de Salud de Castilla-La Mancha | 26 | 48 M | 2020–2026 |
| Gerencia Sector Sanitario de Zaragoza 2 | 72 | 44 M | 2018–2026 |
| Dirección General de Planificación Económica | 18 | 40 M | 2019–2026 |
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 4 | 37 M | 2024–2026 |
and 114 more buyers
Between 2016 and 2026, 95.1% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 749 contracts); followed by Lab & precision instruments (CPV 38), with 1.7%.
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 26/10/2026 | cbam 33-02 am 1001/2023 - roche diagnostics s.l.u. - analizador marcadores cardiacos - agss (cs ron… | Servicio Andaluz de Salud | 1 | €19.6k |
| 26/08/2026 | cbam 34-02 am 1001/2023 - roche diagnostics s.l.u. - analizador de proteina c-reactiva-pcr - cs san… | Servicio Andaluz de Salud | 1 | €10.5k |
| 26/08/2026 | cbam 33-01 am 1001/2023 - roche diagnostics s.l.u. - analizador marcardores cardiacos - suap las la… | Servicio Andaluz de Salud | 1 | no data |
| 26/08/2026 | cbam 33-01 am 1001/2023 - roche diagnostics s.l.u. - analizador marcardores cardiacos - suap las la… | Servicio Andaluz de Salud | 1 | no data |
| 03/08/2026 | huj (dsjjs 2026 fase iv am 837/2023 roche diagnostics, s.l suministro de equipamiento para atención… | Servicio Andaluz de Salud | 1 | €7.00k |